UK markets closed

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.62+0.23 (+3.11%)
At close: 4:00PM EDT
7.61 -0.01 (-0.20%)
After hours: 04:53PM EDT

Autolus Therapeutics plc

Forest House
58 Wood Lane White City
London W12 7RZ
United Kingdom
44 20 3829 6230
http://www.autolus.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees376

Key executives

NameTitlePayExercisedYear born
Dr. Christian Martin ItinCEO & Director4.39MN/A1964
Dr. Martin Pule MBBSFounder, Sr. VP & Chief Scientific OfficerN/AN/A1972
Mr. Andrew J. OakleySr. VP & CFON/AN/A1962
Mr. Christopher VannSr. VP & COON/AN/A1965
Mr. David BrochuSr. VP & Chief Technical OfficerN/AN/A1956
Dr. Lucinda Crabtree Ph.D.VP of IR & Corp. CommunicationsN/AN/AN/A
Mr. Vishal MehtaVP & Head of Clinical OperationsN/AN/AN/A
Mr. Brent RiceVP & Chief Commercial OfficerN/AN/AN/A
Mr. Matthias AlderSr. VP, Chief Bus. Officer & Sec.N/AN/A1965
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

Corporate governance

Autolus Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.